


CLAIMS

1. A compound of formula



5 wherein

m is 0, 1, 2, 3 or 4;

each R¹ independently represents halogen, cyano, hydroxyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₁-C₆ alkylsulphonyl or sulphonamido;

X represents a bond or -CH₂- and Y represents a bond or -CH₂-, provided that X and Y do not both simultaneously represent a bond or -CH₂-;

n is 0, 1 or 2;

each R² independently represents halogen, C₁-C₆ alkyl or C₁-C₆ haloalkyl;

q is 0 or 1;

R³ represents a saturated or unsaturated 5- to 10-membered ring system other than phenyl, which ring system may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen, cyano, oxo, nitro, hydroxyl, carboxyl, -C(O)H, -NR⁹R¹⁰, -C(O)NR¹¹R¹², -NHC(O)R¹³, -NHSO₂R¹⁴, -SO₂NR¹⁵R¹⁶, -NHC(O)NR¹⁷R¹⁸, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylsulphonyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxyC₁-C₆ alkyl, C₁-C₆ alkylcarbonyl, phenylcarbonyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkylmethyl and a saturated or unsaturated 5- to 6-membered heterocyclic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur;

R⁴, R⁵, R⁶, R⁷ and R⁸ each independently represent hydrogen, halogen, C₁-C₆ alkyl or C₁-C₆ haloalkyl;

BEST AVAILABLE COPY

R⁹ and R¹⁰ each independently represent hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl; R¹¹ and R¹² each independently represent hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl, or R¹¹ and R¹² together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring which may be optionally substituted with at least one substituent selected from hydroxyl;

5 R¹³ and R¹⁴ each independently represent C₁-C₆ alkyl, C₃-C₆ cycloalkyl or C₁-C₄ haloalkyl;

10 R¹⁵ and R¹⁶ each independently represent hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl, or R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring which may be optionally substituted with at least one substituent selected from hydroxyl; and

15 R¹⁷ and R¹⁸ each independently represent hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl, or R¹⁷ and R¹⁸ together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring which may be optionally substituted with at least one substituent selected from hydroxyl;

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1, wherein X represents a bond and Y represents -CH₂-.

20

3. A compound according to claim 1 or claim 2, wherein q is 1.

4. A compound according to any one of claims 1 to 3, wherein m is 1 and R¹ represents halogen.

25

5. A compound according to any one of claims 1 to 4, wherein R³ represents an unsaturated 6- to 10-membered ring system other than phenyl, which ring system may comprise one or two ring heteroatoms independently selected from nitrogen and oxygen, or two ring heteroatoms consisting of nitrogen and sulphur, the ring system being optionally substituted with one, two or three substituents independently selected from halogen, oxo,

nitro, -NH₂, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ haloalkyl, C₁-C₄ alkoxyC₁-C₄ alkyl, C₁-C₄ alkylcarbonyl, C₃-C₆ cycloalkylmethyl, -C(O)NR¹¹R¹², carboxyl, and a saturated or unsaturated 5- to 6-membered heterocyclic ring comprising one or two ring heteroatoms independently selected from nitrogen and sulphur.

5

6. A compound according to claim 5, wherein the unsaturated 6- to 10-membered ring system is selected from quinolinyl, 1,2-dihydroquinolinyl, 1,2,3,4-tetrahydroquinolinyl, 2,3-dihydrobenzoxazinyl, 1,2,3,4-tetrahydroquinazolinyl, naphthyl, pyridinyl, benzofuranyl, benzothiazolyl, pyrimidinyl, isoquinolinyl and quinazolinyl.

10

7. A compound according to any one of claims 1 to 6, wherein R⁴, R⁵, R⁶, R⁷ and R⁸ each independently represent hydrogen.

8. A compound according to claim 1 selected from:

15 8-{{(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl}oxy}-3,4-dihydroquinolin-2(1H)-one,

8-{{(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl}oxy}quinolin-2(1H)-one,

20 5-{{(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl}oxy}-2H-1,4-benzoxazin-3(4H)-one,

8-{{(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl}oxy}quinazoline-2,4(1H,3H)-dione trifluoroacetate (salt),

(2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(1-naphthyl)propan-2-ol trifluoroacetate (salt),

25 (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(6-methyl-2-nitropyridin-3-yl)oxy]propan-2-ol trifluoroacetate (salt),

1-(6-{{(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl}oxy}-4,7-dimethoxy-1-benzofuran-5-yl)ethanone trifluoroacetate (salt),

30 (2S)-1-[(6-Chloropyridin-2-yl)oxy]-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol trifluoroacetate (salt),


- (2*S*)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{{[7-(trifluoromethyl)quinolin-4-yl]oxy}propan-2-ol trifluoroacetate (salt),
5 (2*S*)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2-iodo-6-methylpyridin-3-yl)oxy]propan-2-ol trifluoroacetate (salt),
(2*S*)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{{[5-(cyclopropylmethyl)-6-methyl-2-pyridin-4-yl]pyrimidin-4-yl]oxy}propan-2-ol trifluoroacetate (salt),
10 (2*S*)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(quinolin-8-yloxy)propan-2-ol trifluoroacetate (salt),
(2*S*)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(isoquinolin-5-yloxy)propan-2-ol trifluoroacetate (salt),
15 (2*S*)-1-[(6-Bromoquinazolin-4-yl)oxy]-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol trifluoroacetate (salt),
(2*S*)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{{[2-(2-thienyl)-6-trifluoromethyl]pyrimidin-4-yl]oxy}propan-2-ol trifluoroacetate (salt),
20 (2*S*)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(quinolin-5-yloxy)propan-2-ol trifluoroacetate (salt),
(2*S*)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2,3,4-trichloro-1-naphthyl)oxy]propan-2-ol trifluoroacetate (salt),
25 (2*S*)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-{{[1-(1,3-dithiolan-2-yl)-2-naphthyl]oxy}propan-2-ol trifluoroacetate (salt),
(2*S*)-1-{{[5-Butyl-6-(methoxymethyl)-2-(methylthio)pyrimidin-4-yl]oxy}-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol trifluoroacetate (salt),
(2*S*)-1-[(2-Amino-1,3-benzothiazol-4-yl)oxy]-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,
30 (2*S*)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2-methyl-1,3-benzothiazol-4-yl)oxy]propan-2-ol,
(2*S*)-1-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[(2-methyl-1-benzofuran-4-yl)oxy]propan-2-ol,

REST AVAILABLE COPY


3-[(2*S*)-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}isonicotinic acid,
 3-[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-*N*-methylisonicotinamide,
 5 (3*S*)-1-(3-[(2*S*)-3-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}isonicotinoyl)pyrrolidin-3-ol,
 and pharmaceutically acceptable salts and solvates of any one thereof.

9. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in claim 1 which comprises,

10 (a) reacting a compound of formula




wherein m, R¹, n, R², q, X and Y are as defined in formula (I), with a compound of formula




15

wherein R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are as defined in formula (I); or

(b) reacting a compound of formula




wherein m, R¹, n, R², q, X, Y, R⁴, R⁵, R⁶, R⁷ and R⁸ are as defined in formula (I), with a compound of formula



wherein R³ is as defined in formula (I), in the presence of a suitable base;

5

(c) when R³ is substituted with -C(O)NR¹¹R¹², reacting a compound of formula



10

wherein L represents a leaving group (e.g. a hydroxyl group), R^{3'} is a saturated or unsaturated 5- to 10-membered ring system other than phenyl, which ring system may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, and m, R¹, n, R², q, X, Y, Z, R⁴, R⁵, R⁶, R⁷ and R⁸ are as defined in formula (I), with a compound of formula (VII).



wherein R¹¹ and R¹² are as defined in formula (I), in the presence of a suitable coupling reagent;

and optionally after (a), (b) or (c) forming a pharmaceutically acceptable salt or solvate.

10. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 5 11. A process for the preparation of a pharmaceutical composition as claimed in claim 10 which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 10 12. A compound of formula (I) or a pharmaceutically-acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 for use in therapy.
- 15 13. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.
- 20 14. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating rheumatoid arthritis.
- 25 15. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating chronic obstructive pulmonary disease.
16. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating asthma.

BEST AVAILABLE COPY

17. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating multiple sclerosis.

- 5 18. A method of treating an inflammatory disease which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8.
- 10 19. A method of treating an airways disease which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8.

BEST AVAILABLE COPY